Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin |
| |
| Institution: | 1. Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy;2. Department of Biology, University of Padova, Padova, Italy;3. Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy;4. Surgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy;5. Surgical Clinic, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy;1. Department of Pharmacology, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang 050017, China;2. Department of Cardiology, Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang 050000, China;3. Department of Pathology, School of Basic Medicine, Hebei University of Chinese Medicine, 3 Xinyuan Road, Luquan, Shijiazhuang 050200, China;1. Radiopharmacy Center, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes, 2242, São Paulo, 05508-000, Brazil;2. School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bloco 17, São Paulo, 05508-900, Brazil;3. Department of Gastroenterology, Hospital das Clínicas, Av. Enéas C. Aguiar, 255, 9th Floor, Rm 9077, São Paulo, 05403-900, Brazil;1. Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China;2. Department of Endocrinology & Metabolism, Huashan Hospital, Fudan University, Shanghai, China;3. Department of Endocrinology & Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China |
| |
| Abstract: | Metformin, α-glucosidase inhibitors (α-GIs), and dipeptidyl peptidase 4 inhibitors (DPP-4Is) reduce hyperglycemia without excessive insulin secretion, and enhance postprandial plasma concentration of glucagon-like peptide-1 (GLP-1) in type-2 diabetes mellitus (T2DM) patients. We assessed add-on therapeutic effects of DPP-4I anagliptin in Japanese T2DM patients treated with metformin, an α-GI miglitol, or both drugs on postprandial responses of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), and on plasma concentration of the appetite-suppressing hormone leptin. Forty-two Japanese T2DM patients with inadequately controlled disease (HbA1c: 6.5%–8.0%) treated with metformin (n = 14), miglitol (n = 14) or a combination of the two drugs (n = 14) received additional treatment with anagliptin (100 mg, p.o., b.i.d.) for 52 weeks. We assessed glycemic control, postprandial responses of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), and on plasma concentration of leptin in those patients. Add-on therapy with anagliptin for 52 weeks improved glycemic control and increased the area under the curve of biologically active GLP-1 concentration without altering obesity indicators. Total GIP concentration at 52 weeks was reduced by add-on therapy in groups treated with miglitol compared with those treated with metformin. Add-on therapy reduced leptin concentrations. Add-on therapy with anagliptin in Japanese T2DM patients treated with metformin and miglitol for 52 weeks improved glycemic control and enhanced postprandial concentrations of active GLP-1/total GIP, and reduce the leptin concentration. |
| |
| Keywords: | Type-2 diabetes mellitus DPP-4I GLP-1 &alpha Metformin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
